Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arvinas, Inc. - Common Stock
(NQ:
ARVN
)
6.640
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arvinas, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
May 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
May 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
May 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Earnings Scheduled For May 1, 2025
May 01, 2025
Via
Benzinga
ARVINAS ALERT: Bragar Eagel & Squire, P.C. is Investigating Arvinas, Inc. on Behalf of Arvinas Stockholders and Encourages Investors to Contact the Firm
May 07, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Where Arvinas Stands With Analysts
May 05, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
May 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
May 02, 2025
Via
Benzinga
Here are the top movers in Thursday's session.
May 01, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Top stock movements in today's session.
May 01, 2025
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Dow Surges Over 300 Points; McDonald's Posts Weak Revenue
May 01, 2025
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
May 01, 2025
Via
Benzinga
The market is filled with gapping stocks in Thursday's session.
May 01, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via
Chartmill
Nasdaq Jumps 1.5%; Microsoft Posts Upbeat Results
May 01, 2025
Via
Benzinga
These stocks are moving in today's pre-market session
May 01, 2025
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 01, 2025
Via
Benzinga
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 01, 2025
From
Arvinas Inc.
Via
GlobeNewswire
A Peek at Arvinas's Future Earnings
April 30, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 30, 2025
Via
Benzinga
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
April 28, 2025
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
April 28, 2025
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
April 21, 2025
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
April 04, 2025
Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.
Via
Benzinga
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
April 04, 2025
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
March 27, 2025
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2...
From
Arvinas Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks That Are Set To Fly This Month
March 26, 2025
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday
March 12, 2025
Via
Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
March 12, 2025
Via
Benzinga
Tuesday's session: top gainers and losers
March 11, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.